ILIKA PLC
IGE | IL
Overview
Corporate Details
- ISIN(s):
- GB00B608Z994 (+2 more)
- LEI:
- 213800TMDNIE3Z8XXD26
- Country:
- United Kingdom
- Address:
- UNIT 10A, THE QUADRANGLE, SO51 9DL ROMSEY
- Website:
- https://www.ilika.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ImmuPharma is an AIM-listed biopharmaceutical company developing peptide-based therapies for autoimmune diseases and anti-infectives.Ê Its lead program, P140, is in Phase 3 trials for SLE.Ê The company aims to build a robust pipeline through strategic partnerships and licensing, maximizing shareholder value.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-17 09:56 |
Major Shareholding Notification
Holding(s) in Company
|
English | 40.0 KB | |
| 2025-07-17 08:00 |
Earnings Release
Final Results
|
English | 770.9 KB | |
| 2025-07-15 08:00 |
Regulatory News Service
Award of Government Grant Funding
|
English | 15.4 KB | |
| 2025-06-11 15:09 |
Report Publication Announcement
Notice of Results
|
English | 12.7 KB | |
| 2025-06-03 14:57 |
Major Shareholding Notification
Holding(s) in Company
|
English | 22.5 KB | |
| 2025-05-22 15:16 |
Share Issue/Capital Change
Retail Offer for up to £0.5 million
|
English | 43.6 KB | |
| 2025-05-07 11:03 |
Report Publication Announcement
Ilika announces 2025 Investor Day
|
English | 12.4 KB | |
| 2025-03-06 08:00 |
Regulatory News Service
Goliath Development Progress
|
English | 14.6 KB | |
| 2025-02-27 08:00 |
Share Issue/Capital Change
Award & Exercise of Share Options
|
English | 98.2 KB | |
| 2025-02-06 16:49 |
Major Shareholding Notification
Holding(s) in Company
|
English | 21.9 KB | |
| 2025-02-05 08:00 |
Regulatory News Service
Goliath Scale-up Progress
|
English | 15.1 KB | |
| 2025-01-21 08:00 |
Interim Report
Half-year Results
|
English | 178.2 KB | |
| 2025-01-09 08:00 |
Regulatory News Service
Stereax Equipment Commissioning Completed
|
English | 14.4 KB | |
| 2024-12-19 08:00 |
Board/Management Information
Appointment of Nominated Adviser and Sole Broker
|
English | 9.8 KB | |
| 2024-11-22 15:18 |
Board/Management Information
AIM Rule 17 Schedule 2(g) Update
|
English | 13.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
| TORII PHARMACEUTICAL CO., LTD. | Japan | 4551 | ||
|
TOWA PHARMACEUTICAL CO.,LTD. | Japan | 4553 | |
|
TSUMURA & CO. | Japan | 4540 | |
|
TURK İLAÇ VE SERUM SANAYİ A.Ş. | Türkiye | TRILC | |
|
UCB | Belgium | UCB | |
|
Valneva SE | France | VLA | |
|
VENTURE LIFE GROUP PLC | United Kingdom | VLG | |
|
Vetoquinol SA | France | VETO | |
|
Vicore Pharma Holding | Sweden | VICO | |
|
Vifor Pharma AG | Switzerland | VIFN |